Abstract
Cardiovascular diseases are the leading cause of morbidity and mortality in diabetic patients. For several years, it has been required that new hypoglycemic medications undergo cardiovascular safety studies for approval. In 2015, the EMPA-REG OUTCOME, conducted for the approval of empagliflozin, a new sodium-glucose cotransporter 2 inhibitor, was the first study to provide evidence that a…